Humanized antibodies that recognize alpha-synuclein

Patent metadata

Field	Value
Publication number	US-9670273-B2
Application number	US-201514937792-A
Country	US
Kind code	B2
Filing date	Nov 10, 2015
Priority date	Jan 27, 2012
Publication date	Jun 6, 2017
Grant date	Jun 6, 2017

Abstract

The present application discloses humanized 1H7 antibodies. The antibodies bind to human alpha synuclein and can be used for treatment and diagnosis of Lewy body disease.

First claim

What is claimed is:

1. A method of detecting abnormal deposits of alpha-synuclein in a patient having or at risk of a Lewy body disease, comprising administering to the patient an effective amount of an antibody comprising a mature heavy chain variable region comprising the three Kabat CDRs of SEQ ID NO:44, and being at least 90% identical to SEQ ID NO:44, and a light chain comprising the three Kabat CDRs of SEQ ID NO:45, and being at least 90% identical to SEQ ID NO:45, wherein the antibody binds to aggregated synuclein; and detecting bound antibody in the patient.

2. The method of claim 1 , wherein the mature heavy chain variable region is at least 95% identical to SEQ ID NO:44 and mature light chain variable region is at least 95% identical to SEQ ID NO:45.

3. The method of claim 1 , wherein the mature heavy chain variable region has an amino acid sequence at least 98% identical to SEQ ID NO:44 and the mature light chain variable region has an amino acid sequence at least 98% identical to SEQ ID NO:45.

4. The method of claim 1 , wherein the mature heavy chain variable region has an amino acid sequence at least 99% identical to SEQ ID NO:44 and the mature light chain variable region has an amino acid sequence at least 99% identical to SEQ ID NO:45.

5. The method of claim 1 , wherein the amino acid sequence of the mature heavy chain variable region is SEQ ID NO:44 and the amino acid sequence of the mature light chain variable region is SEQ ID NO:45 except provided that position L46 (Kabat numbering) can be occupied by L or F and/or position L49 (Kabat numbering) can be occupied by Y or C and/or position L83 (Kabat numbering) can be occupied by F or A, and/or position H11 (Kabat numbering) can be occupied by V or L, and/or position H28 (Kabat numbering) can be occupied by T or S, and/or position H38 (Kabat numbering) can be occupied by R or K, and/or position H48 (Kabat numbering) can be occupied by M or I, and/or position H67 (Kabat numbering) can be occupied by V or A, and/or position H69 (Kabat numbering) can be occupied by M or L, and/or position H71 (Kabat numbering) can be occupied by T or A, and/or position H91 (Kabat numbering) can be occupied by Y or F, and/or H97 (Kabat numbering) can be occupied by C or S.

6. The method of claim 5 , wherein position H11 (Kabat numbering) is occupied by V, position H28 (Kabat numbering) is occupied by S, position H38 (Kabat numbering) is occupied by R, position H48 (Kabat numbering) is occupied by I, position H67 (Kabat numbering) is occupied by A, position H69 (Kabat numbering) is occupied by L, position H71 (Kabat numbering) is occupied by A, position H91 (Kabat numbering) is occupied by F and position H97 (Kabat numbering) is occupied by C.

7. The method of claim 1 comprising a humanized heavy chain comprising the three Kabat CDRs of SEQ ID NO:44 and a humanized light chain comprising the three CDRs of SEQ ID NO:45 provided that position L46 (Kabat numbering) is occupied by F and/or position L49 (Kabat numbering) is occupied by C and/or position L83 (Kabat numbering) is occupied by F, and/or position H11 (Kabat numbering) is occupied by V, and/or position H28 (Kabat numbering) is occupied by T, and/or position H38 (Kabat numbering) is occupied by R, and/or position H48 (Kabat numbering) is occupied by M, and/or position H67 (Kabat numbering) is occupied by A, and/or position H69 (Kabat numbering) is occupied by M, and/or position H71 (Kabat numbering) is occupied by A, and/or position H91 (Kabat numbering) is occupied by Y, and/or position H97 (Kabat numbering) is occupied by C.

8. The method of claim 7 , wherein position L46 (Kabat numbering) is occupied by F, position L49 (Kabat numbering) is occupied by C, position L83 (Kabat numbering) is occupied by F, position H11 (Kabat numbering) is occupied by V, H28 (Kabat numbering) is occupied by T, position H38 (Kabat numbering) is occupied by R, position H48 (Kabat numbering) is occupied by M, position H67 (Kabat numbering) is occupied by A, position H69 (Kabat numbering) is occupied by M, position H71 (Kabat numbering) is occupied by A, position H91 (Kabat numbering) is occupied by Y, and H97 (Kabat numbering) is occupied by C.

9. The method of claim 1 comprising a mature heavy chain variable region having an amino acid sequence at least 90% identical to SEQ ID NO:23 and a mature light chain variable region at least 90% identical to SEQ ID NO:37.

10. The method of any preceding claim, wherein the mature heavy chain variable region is fused to a heavy chain constant region and the mature light chain variable region is fused to a light chain constant region.

11. The method of claim 1 , wherein the antibody is labeled.

12. The method of claim 1 or 11 , wherein the disease is Parkinson's disease.

13. The method of claim 11 , wherein the label is a fluorescent label.

14. The method of claim 11 , wherein the label is a paramagnetic label.

15. The method of claim 11 , wherein the label is a radioactive label.

16. The method of claim 1 , wherein the antibody is unlabeled and a secondary labeling agent is used to bind to the antibody.

17. The method of claim 1 , wherein the antibody is an antibody fragment lacking a full-length constant region.

18. The method of claim 17 , wherein the antibody is a Fab.

19. The method of claim 1 , wherein the antibody is administered by intravenous injection.

20. The method of claim 1 , wherein the antibody is administered by intracranial injection.

21. The method of claim 11 , wherein the label is detected using PET or SPECT.

Assignees

• Prothena Biosciences Ltd

Inventors

• Saldanha Jose
• Nijjar Tarlochan S

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P25/16

  Anti-Parkinson drugs · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• C07K2317/56

  variable (Fv) region, i.e. VH and/or VL · CPC title